SINOVAC BIOTECH LTD (SVA)
About SINOVAC BIOTECH LTD
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its products include vaccines for hepatitis A, hepatitis B, EV-A71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella, mumps, and tetanus. The Company generates maximum revenue from Mainland China.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $386.0M
- Net income
- -$13.5M
- Total assets
- $8.5B
Source: SEC EDGAR · updated Jun 8, 2026
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 26, 2003
No reviews yet. Be the first to review SINOVAC BIOTECH LTD.
Write a review
Sinovac Biotech Ltd: frequently asked questions
Is Sinovac Biotech Ltd an American company?
Sinovac Biotech Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Sinovac Biotech Ltd publicly traded?
Yes — Sinovac Biotech Ltd is a publicly traded company. Its stock trades under the ticker symbol SVA on the NASDAQ.
What does Sinovac Biotech Ltd do?
Sinovac Biotech Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
When was Sinovac Biotech Ltd founded?
Sinovac Biotech Ltd was founded in 1999.
